Myogen Inc

Myogen — Investor Presentation (October 2005)

33 slides from Myogen's investor presentation, Oct 3, 2005

  1. Slide 1: Innovative therapies targeting cardiovascular disease

    Innovative therapies M targeting cardiovascular disease Nasdaq: MYOG October 2005

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Some of the matters discussed in this presentation contain forward-looking statements that involve significant risks and uncertainties, including statements relating to the completion and reporting of results from the Company's clinical trials and the potential advantages

  3. Slide 3: Myogen Highlights

    Myogen Highlights Therapeutics for Cardiovascular Diseases Late-stage Product Pipeline Ambrisentan for PAH (pivotal Phase 3 trials on-going) Darusentan for RHTN (positive Phase 2b results - August 2005) Marketed Product in Europe Commercial Rights Retained Integrated Target and Drug Discovery Platfo

  4. Slide 4: Management Team

    Management Team Bill Freytag, PhD President & CEO Michael Bristow, MD, PhD Chief Medical & Science Officer Michael Gerber, MD SVP Clinical Development & Regulatory Affairs Rick Gorczynski, PhD SVP Research & Development John Julian SVP Commercial Development Joe Turner SVP Finance & CFO Andrew Dicki

  5. Slide 5: Business Strategy

    Business Strategy Selectively in-license and acquire drugs in clinical development for which we have a unique ability to add value Leverage our understanding of heart failure at the molecular level in the discovery and development of disease modifying therapeutics

  6. Slide 6: Myogen Product Portfolio

    Myogen Product Portfolio Myogen Product Potential Indication Phase2 Phase3 Marketed Perfan® 1LV. Acute Decompensated (.v.enoximone) Heart Failure ; Pulmonary Arterial Resistant Darusentan ypenareton Cardiac Hypertrophic Heart Failure Discovery Signaling

  7. Slide 7: Myogen Product Portfolio

    Myogen Product Portfolio Myogen Product Potential Indication Perfan® ILV. Acute Decompensated v.enoximone) Heart Failure Phase2 Phase3 Marketed Resistant Darusentan ; Hypertension Cardiac Hypertrophic Heart Failure Discovery Signaling

  8. Slide 8: Pulmonary Arterial Hypertension (PAH)

    Pulmonary Arterial Hypertension (PAH) Severely debilitating, life-threatening disease Estimated 200,000 individuals worldwide have PAH Multiple etiologies Primary pathogenesis is pulmonary endothelial cell dysfunction or injury leading to: Vasoconstriction Smooth-muscle cell and endothelial cell pro

  9. Slide 9: PAH Therapies (estimated 2004 sales)

    PAH Therapies (estimated 2004 sales) ERAs Prostacyclin Analogs PDE-5 Inhibitors Other Sales 372.89 311.91 2 5.671 Total: $690.5 million Endothelin Receptor Antagonists 54% Prostacyclin Analogs 45% CCBs, Vit. K Antagonists, Diuretics 1% PDE-5 Inhibitors 0% Sources: Decision Resources PAH Cardium (2/2

  10. Slide 10: Ambrisentan

    Ambrisentan ETA-selective (260X) ETA receptor occupancy = 82-97% ETB receptor occupancy = 2-7% High potency and oral bioavailability Long half-life (9-15 hours) No significant p450 induction or inhibition No active metabolite - excreted in feces Linear pharmacokinetics Patent protection through 2015

  11. Slide 11: Ambrisentan Potential Advantages

    Ambrisentan Potential Advantages Efficacy Significant improvements in exercise capacity and symptoms Durable efficacy Comparable efficacy in Class II and Class III Dose flexibility Safety profile and ease of use True once daily dosing No drug-drug interactions with other PAH therapies Low incidence

  12. Slide 12: Ambrisentan Clinical Program

    Ambrisentan Clinical Program Phase 1 Phase 2 Phase 3 Healthy Volunteers Single Dose 63 subjects Healthy Volunteers Multiple Dose 30 subjects, 10 days AMB-220 Dose-Ranging 64 subjects, 12 wk Open-label Extension 12 wk Phase 2 Long-term AMB-220-E Phase 3 AMB-320 (ARIES-1) Primarily U.S. 186 subjects,

  13. Slide 13: Change in 6MWD across ERA trials

    50 60 - -20 - -10 0 10 20 30 40 Change in 6MWD (meters) Bosentan BREATHE-1 n = 74 Sitaxsentan STRIDE I&II n= 55/62 placebo 100 mg 12 wks 18 wks 1-10 mg 12 wks 16 wks placebo 125 mg 16 wks Ambrisentan AMB-220 n= 64 Ambrisentan demonstrated significant efficacy 1- Rubin et al., Ambrisentan Improves Ex

  14. Slide 14: Ambrisentan demonstrated significant efficacy

    1 2 Ambrisentan demonstrated significant efficacy 1- Rubin et al., Ambrisentan Improves Exercise Capacity and Clinical Measures in PAH, 2004 Abstracts for the American Thoracic Society. 2- FDA Briefing Document on Tracleer for CardioRenal Advisory Panel, August 10, 2001 and Tracleer Product Labeling

  15. Slide 15: Comparable efficacy in Class II and Class III patients

    Baseline 6MWD: Class II=390 m; Class III=316 m 0 10 20 30 40 50 60 70 80 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 Class II (n=23) Class III (n=41) Change in 6MWD (meters) Ambrisentan demonstrated comparable efficacy in patients with Class II and Class III symptoms

  16. Slide 16: Significant improvements in disease symptoms

    0 20 40 60 80 100 0 2 4 8 12 16 20 24 Class I Class II Class III Class IV n=64 n=62 n=62 n=58 n=58 n=55 n=54 n=54 Percent Week Ambrisentan demonstrated significant improvements in disease symptoms

  17. Slide 17: Ambrisentan demonstrated durable efficacy

    Week 0 Week 12 Week 24 Week 48 6MWD, n 64 64 64 64 6MWD, meters 343 379 397 397 Dyspnea, n 63 64 64 64 Dyspnea, Borg index 4.0 3.1 2.7 3.1 WHO Functional Class, n 64 64 64 64 Class I, % 0 11 12 11 Class II, % 36 48 47 48 Class III, % 64 41 41 41 Class IV, % 0 0 0 0 Ambrisentan demonstrated durable e

  18. Slide 18: Ambrisentan apparent survival benefit

    50 60 70 80 90 100 100 200 300 Days Event-free patients (%) IPAH Patients, n = 39 92% Observed Survival vs 74% Predicted Survival Observed Survival Survival from NIH Registry Ambrisentan apparent survival benefit

  19. Slide 19: Well tolerated with low incidence of liver toxicity

    0 5 10 15 20 25 30 LFTs >8X LFTs >3X Flushing Nausea Headache Nasal Congestion Upper Respiratory Tract Symptoms Peripheral Edema Percent of Patients with AE (%) Ambrisentan was well tolerated with low incidence of potential liver toxicity

  20. Slide 20: Ambrisentan Clinical Program

    Ambrisentan Clinical Program Phase 1 Phase 2 Phase 3 Healthy Volunteers Single Dose 63 subjects Healthy Volunteers Multiple Dose 30 subjects, 10 days AMB-220 Dose-Ranging 64 subjects, 12 wk Open-label Extension 12 wk Phase 2 Long-term AMB-220-E Phase 3 AMB-320 (ARIES-1) Primarily U.S. 186 subjects,

  21. Slide 21: Ambrisentan Potential Advantages

    Ambrisentan Potential Advantages Efficacy Significant improvements in exercise capacity and symptoms Durable efficacy Comparable efficacy in Class II and Class III Dose flexibility Safety profile and ease of use True once daily dosing No drug-drug interactions with other PAH therapies Low incidence

  22. Slide 22: PAH may be the first of several pulmonary disorders that respond to ERAs

    PAH may be the first of several pulmonary disorders that respond to ERAs WHO CLASSIFICATION OF PULMONARY HYPERTENSION Pulmonary arterial hypertension Idiopathic Familial Associated with Collagen vascular disease Congenital left-to-right shunt Portal hypertension Infection with HIV Drugs and toxins P

  23. Slide 23: Myogen Product Portfolio

    Myogen Product Portfolio Myogen Product Potential Indication Precli al Phase’ | Phase? Phase3 Marketed Acute Decompensated Heart Failure Pulmonary Arterial Hypertension Ambrisentan Cardiac Hypertrophic Heart Failure Discovery Signaling 22

  24. Slide 24: Resistant Hypertension

    Resistant Hypertension 65 million individuals in US (~1B worldwide) have hypertension Despite use of multiple drug classes many remain hypertensive leading to cardiovascular events JNC 7 defines resistant hypertension as: "the failure to achieve goal blood pressure in patients who are adhering to fu

  25. Slide 25: Prevalence of Resistant Hypertension

    Prevalence of Resistant Hypertension Prevalent Population (2005)* (~65 million in the US) Diagnosed & Treated Population* (~39 million in the US) ~10-30% of Patients on Therapy Do Not Reach Target BP (4-12 million)* * Myogen, Inc. estimates based on syndicated data sources, claims data (2003,2004) a

  26. Slide 26: Darusentan Characteristics

    Darusentan Characteristics ETA-selective Potential once daily dosing Approximately 1,500 patients studied in prior trials Potent anti-hypertensive properties Well tolerated No evidence of liver toxicity Darusentan is a second-generation ERA with a large safety database

  27. Slide 27: Darusentan Phase 2b Trial Design

    10 mg 50 mg 100 mg 150 mg 300 mg Study Week - -2 0 4 6 Randomization Placebo Treatment Period - -4 Screening Period Placebo Run-in Withdrawal 10 8 2 100 mg 11 12 Final Safety Visit P P 115 patients randomized 2:1 Darusentan Phase 2b Trial Design

  28. Slide 28: Darusentan Phase 2b Results

    Darusentan Phase 2b Results Achieved primary efficacy endpoint: - -11.6 mmHg reduction in systolic b.p. (p = 0.02) - -5.8 mmHg reduction in diastolic b.p. (p<0.004) Clinically meaningful reductions in systolic and diastolic b.p. at earlier time points at lower doses Favorable safety profile - genera

  29. Slide 29: Darusentan Potential

    Darusentan Potential Possible first ERA approved for hypertension (major new class) No drug-drug interactions (combination therapy) Once daily dosing Dosing flexibility Long patent life (2015) Darusentan could be the first of a new class of agents for treating resistant hypertension

  30. Slide 30: Integrated Target & Drug Discovery Platform

    Integrated Target & Drug Discovery Platform Intact human heart gene expression Human cardiomyocyte culture Molecular Targets for Heart Failure Assays, High Throughput Screening & Drug Discovery Validation Cardiac signaling pathways Cardiogenomics Cardioproteomics Fetal Gene Program Heart Tissue Bank

  31. Slide 31: Drug Discovery and Development Partnership with Novartis

    Drug Discovery and Development Partnership with Novartis Broad strategic partnership in heart muscle disease Expanded in 2Q 2005 to include HDAC inhibitor program Annual research funding to Myogen for 3 years, annually renewable thereafter Significant commitment of Novartis resources Success milesto

  32. Slide 32: Selected Financial Information

    Selected Financial Information Recently completed sale of 5.4 million shares of common stock for approximate net proceeds of $116 million

  33. Slide 33: 2005 Guidance

    2005 Guidance (as of September 16, 2005)1 Complete ARIES-2 enrollment July 21 Darusentan Phase 2b results August 18 Completed $125M financing September 21 Complete ARIES-1 enrollment Year-end ARIES-2 results December 1- The guidance was effective on the date it was issued and it is our policy not to

Myogen — Investor Presentation (October 2005) on 6ix